RT Journal Article
T1 Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort
A1 Calderón Parra, Jorge
A1 Guisado Vasco, Pablo
A1 Montejano Sánchez, Rocío
A1 Estrada Pérez, Vicente
A1 Cuevas Tascón, Guillermo
A1 Aguareles Gorines, José
A1 Arribas, José
A1 Erro Iribarren, Marta
A1 Calvo Salvador, Marina
A1 Fernández Cruz, Ana
A1 Ramos Martínez, Antonio
A1 Muñez Rubio, Elena
AB Objective: We aim to describe the safety and efficacy of sotrovimab in severe cases of COVID-19 in immunocompromised hosts. Methods: We used a retrospective multicenter cohort including immunocompromised hospitalized patients with severe COVID-19 treated with sotrovimab between October 2021 and December 2021. Results: We included 32 patients. The main immunocompromising conditions were solid organ transplantation (46.9%) and hematological malignancy (37.5%). Seven patients (21.9%) had respiratory progression: 12.5% died and 9.4% required mechanical ventilation. Patients treated within the first 14 days of their symptoms had a lower progression rate: 12.0% vs. 57.1%, p = 0.029. No adverse event was attributed to sotrovimab. Conclusions: Sotrovimab was safe and may be effective in its use for immunocompromised patients with severe COVID-19. More studies are needed to confirm these preliminary data.
PB MDPI
SN 2077-0383
YR 2023
FD 2023
LK https://hdl.handle.net/20.500.14352/72323
UL https://hdl.handle.net/20.500.14352/72323
LA eng
NO This work was supported by the Research Institute Puerta de Hierro-Segovia de Aranda (IDIPHSA), funding number 0040200108 (2.400€).
NO Research Institute Puerta de Hierro-Segovia de Aranda (IDIPHSA)
DS Docta Complutense
RD 30 jun 2024